Cargando…
The Longitudinal Imaging Tracker (BrICS-LIT):A Cloud Platform for Monitoring Treatment Response in Glioblastoma Patients
Glioblastoma is a common and aggressive form of brain cancer affecting up to 20,000 new patients in the US annually. Despite rigorous therapies, current median survival is only 15–20 months. Patients who complete initial treatment undergo follow-up imaging at routine intervals to assess for tumor re...
Autores principales: | Ramesh, Karthik, Gurbani, Saumya S., Mellon, Eric A., Huang, Vicki, Goryawala, Mohammed, Barker, Peter B., Kleinberg, Lawrence, Shu, Hui-Kuo G., Shim, Hyunsuk, Weinberg, Brent D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Grapho Publications, LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289246/ https://www.ncbi.nlm.nih.gov/pubmed/32548285 http://dx.doi.org/10.18383/j.tom.2020.00001 |
Ejemplares similares
-
The Brain Imaging Collaboration Suite (BrICS): A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow
por: Gurbani, Saumya, et al.
Publicado: (2019) -
Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023) -
A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma
por: Ramesh, Karthik K., et al.
Publicado: (2023) -
Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial
por: Trivedi, Anuradha G., et al.
Publicado: (2023) -
A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma
por: Ramesh, Karthik, et al.
Publicado: (2022)